Inhibitor may turn tumor-protecting immune cells against glioblastoma
Mayo Clinic researchers have identified a potential new approach to treating glioblastoma that could help the immune system fight the aggressive brain cancer while improving the effectiveness of existing chemotherapy.
A potential new treatment strategy for glioblastoma, an aggressive brain tumor, may involve harnessing the immune system to fight the cancer while making existing chemotherapy more effective. Researchers at Mayo Clinic have discovered that inhibiting the MALT1 enzyme can reprogram immune cells near glioblastomas, transforming them from collaborating with the tumor to fostering an antitumor response.
Preclinical studies published in Nature Communications revealed that MALT1 inhibition slowed tumor growth and improved the effectiveness of temozolomide, the standard chemo drug for glioblastoma. When MALT1 inhibition was combined with temozolomide in a specific preclinical model, median survival significantly increased compared to temozolomide alone.
Glioblastoma poses significant challenges due to its ability to manipulate the immune cells around it, creating a protective environment. The findings suggest a possible way to disrupt this immune protection and make an existing treatment more potent. Researchers aim to better understand how glioblastoma interacts with the immune cells surrounding the tumor to dampen its anti-tumor response and identify new therapies that boost the immune system's ability to combat the disease.
Further research is needed to determine which glioblastoma subtypes may benefit most from MALT1-targeted therapy and to assess its potential for clinical use.
Written by urgent.news from Medical Xpress's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
